Öz
In chronic hepatitis C patients telaprevir attracts attention with high sustained virologic response and short term treatment however it is associated a new spectrum of adverse events, especially several cutaneous manifestations. We report a 66-year-old female patient developed drug reaction with eosinophilia and systemic symptoms during telaprevir based hepatitis C treatment. All antivirals were discontinued and she was treated with supportive care. Systemic and cutaneous symptoms resolved in follow-up. Although rare, clinicians should be aware of potentially severe cutaneous skin reactions during telaprevir -based therapy.
Anahtar Kelimeler
Kaynakça
- Fontaine H, Pol S. Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-ex- perienced patients. Clin Gastroenterol Hepatol 2011;35:S59- S63.
- Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Gastro- enterol Hepatol 2012;36:437-440.
- Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side effects. Liver Int 2013;33 Supp:30-34.
- Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med 2011;364:2405-2416.
- Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Eng J Med 2011:364:2417-2428.
- Cacoub P, Bourliere M, Lübbe J, et al. Dermatological side ef- fects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. J Hepatol 2012;56:455-463.
- Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-Re- lated Dermatitis. JAMA Dermatol 2013;149:152-158.
Öz
Kronik hepatit C tedavisinde telaprevir yüksek kalıcı viral yanıt ve kısa süreli tedavi özelliğiyle dikkat çekmektedir, ancak özellikle çeşitli cilt yan etkileri olmak üzere yeni yan etkilerle ilişkilidir. Biz telaprevir bazlı hepatit C tedavisi esnasında sistemik semptomlar ve eozinofilinin eşlik ettiği ilaç reaksiyonu gelişen 66 yaşında bir kadın hasta sunduk. Hastanın tüm antiviralleri kesildi ve destek tedavi verildi. Takibinde sistemik ve cilt bulguları düzeldi. Nadir olmasına rağmen telaprevir bazlı tedavi esnasında ciddi cilt reaksiyonları akılda tutulmalıdır
Anahtar Kelimeler
Kaynakça
- Fontaine H, Pol S. Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-ex- perienced patients. Clin Gastroenterol Hepatol 2011;35:S59- S63.
- Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Gastro- enterol Hepatol 2012;36:437-440.
- Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side effects. Liver Int 2013;33 Supp:30-34.
- Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med 2011;364:2405-2416.
- Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Eng J Med 2011:364:2417-2428.
- Cacoub P, Bourliere M, Lübbe J, et al. Dermatological side ef- fects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. J Hepatol 2012;56:455-463.
- Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-Re- lated Dermatitis. JAMA Dermatol 2013;149:152-158.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Bölüm | Olgu Sunumu |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Nisan 2015 |
| Yayımlandığı Sayı | Yıl 2015 Cilt: 5 Sayı: 01 |